This is a working overview of Proline-rich sequence, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-12-10. Anything still debated is marked as such rather than presented as settled.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | computed for the free peptide |
| Molecular weight | about 1419 Da | monoisotopic mass near 1418.7 |
| Amino acid count | 15 | single chain, no disulfide bonds |
| Solubility | freely soluble in water | also dissolves in saline and phosphate buffer |
| Common synonyms | pentadecapeptide BPC, BPC 157 | fragment notation varies by source |
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
=== January === 1 January Helen Hogan, educator (Hillmorton High School, WEA), editor of poetry anthologies, and Māori studies scholar (born 1923). Lyn Fleming, Police senior sergeant and first policewoman in New Zealand to be killed in the line of duty (born 1963). 2 January – Lex Clark, Olympic rower (1964) (born 1943). 3 January Kate Coolahan, commercial artist, fashion illustrator, printmaker, and design educator (Wellington Polytechnic) (born 1929). Dame Tariana Turia, politician, Labour list MP (1996–2002), MP for Te Tai Hauāuru (2002–2014), co-leader of the Māori Party (2004–2014), Minister for the Community and Voluntary Sector (2003–2004, 2008–2011), Minister for Disability Issues (2009–2014), Minister for Whānau Ora (2010–2014) (born 1944). 5 January Philippa Blair, artist (born 1945). Lou Robinson, structural engineer and heritage advocate (born 1943). 7 January – Arthur Pomeroy, classical scholar (Victoria University of Wellington), chess player and administrator (born 1953). 18 January – Russell Marshall, politician and diplomat, MP for Wanganui (1972–1990), Minister of Education (1984–1987), Minister of Foreign Affairs (1987–1990), chancellor of Victoria University of Wellington (2000–2002), High Commissioner to the United Kingdom (2002–2005) (born 1936). 19 January – David Johnston, disaster researcher (Massey University) (born 1966). 20 January – Richard Hipa, Niuean public servant and politician, Secretary of Government (2008–2017), Member of the Niue Assembly (2020–2023) (born 1957). 21 January Diana Beaglehole, historian (born 1938).
== P == Pacinian corpuscle A type of rapidly adapting mechanoreceptor located deep in the skin, responsible for detecting vibration and pressure. Pain An unpleasant sensory and emotional experience associated with actual or potential tissue damage. In neuroscience, pain is studied through nociception, pain pathways, and perception. Paralysis The loss of voluntary muscle function, often caused by damage to the brain, spinal cord, or peripheral nerves. Paraneoplastic syndrome A rare disorder triggered by an immune response to cancer that affects the nervous system. Can lead to sensory, motor, or cognitive symptoms. Parietal lobe A region of the cerebral cortex located near the top and back of the brain, involved in processing somatosensory information, spatial orientation, and body awareness. Parkinson’s disease A neurodegenerative disorder characterized by tremors, rigidity, bradykinesia, and postural instability. Caused by loss of dopaminergic neurons in the substantia nigra. Parvocellular pathway A visual processing stream originating in small ganglion cells of the retina, responsible for high-acuity and color vision. Projects to the lateral geniculate nucleus. Periaqueductal gray (PAG) A midbrain region involved in pain modulation, defensive behavior, and autonomic regulation. Contains opioid receptors and descending pain control pathways. Peripheral nervous system (PNS) All nerves and ganglia outside the brain and spinal cord. It includes sensory and motor neurons as well as autonomic nerves. Periventricular Located near or surrounding the brain’s ventricular system.
Evidence is insufficient to support the use of medications to treat obstructive sleep apnea directly. This includes the use of fluoxetine, paroxetine, acetazolamide, and tryptophan among others. Recent studies are trying to investigate cannabinoids as a treatment for OSA, especially dronabinol, which is a synthetic form of THC (delta-9-tetrahydrocannabinol). Cannabis is known to influence sleep; for example, it can reduce sleep latency. However, results are not consistent. Studies about dronabinol have shown positive impact on the OSA, as they observed a reduced AHI (Apnea-Hypopnea Index) and an increased self-reported sleepiness (the objective sleepiness being unaffected). However, more evidence are needed as many effects of those substances remain unknown, especially the effects of a long-term intake. The effects on sleepiness and weight gain are particularly of concern. Due to uncertainty about its effects and a lack of consistent evidence, medical cannabis is not recommended for the treatment of OSA. There are multiple drugs approved for managing the excessive daytime sleepiness associated with OSA, but not the underlying cause. These include solriamfetol, modafinil, and armodafinil. For adults with obesity and moderate-to-severe OSA, during a 52-week study tirzepatide (brand name Zepbound) substantially reduced apneic-hypopnic events, body weight, hypoxic burden, hsCRP concentration, and systolic blood pressure, and improved sleep-related patient-reported outcomes, all presumably mediated via induced weight loss of 18–20% from baseline.
The LSD molecule has two chiral centers at carbons 5 and 8 of the ergoline ring system and hence there are four possible enantiomeric stereoisomers of LSD. Iso-LSD, also known as d-iso-LSD, (+)-iso-LSD, or (5R-8S)-LSD, is one of four possible stereoisomers. The other isomers are LSD (d-LSD, (+)-LSD, or (5R,8R)-LSD), l-iso-LSD ((–)-iso-LSD or (5S,8R)-iso-LSD), and l-LSD ((–)-LSD or (5S,8S)-LSD). None of them are known to have significant psychoactivity in humans besides LSD. LSD is easily epimerized into iso-LSD with base. Consequently, iso-LSD is a common synthetic contaminant in chemical synthesis of LSD. Iso-LSD can be easily epimerized back into LSD. LSD can degrade into iso-LSD depending on temperature, solvent and pH, among other factors. In clinical studies, up to 30% of LSD administered in capsules has been found to isomerize into iso-LSD. Iso-LSD is said to be a metabolite of LSD in animals and humans. However, according to other sources, iso-LSD not a metabolite of LSD but is instead only a contaminant.
Sources: en.wikipedia.org
== Other animals == Inactivity and starvation in mammals lead to atrophy of skeletal muscle, accompanied by a smaller number and size of the muscle cells as well as lower protein content. In humans, prolonged periods of immobilization, as in the cases of bed rest or astronauts flying in space, are known to result in muscle weakening and atrophy. Such consequences are also noted in small hibernating mammals like the golden-mantled ground squirrels and brown bats. A striking example of human-induced atrophy is seen in Amar Bharati, an Indian sadhu who held his arm raised for decades as a spiritual devotion, resulting in severe muscle atrophy and loss of function in the limb. Bears are an exception to this rule; species in the family Ursidae are famous for their ability to survive unfavorable environmental conditions of low temperatures and limited nutrition availability during winter by means of hibernation. During that time, bears go through a series of physiological, morphological, and behavioral changes. Their ability to maintain skeletal muscle number and size during disuse is of significant importance. During hibernation, bears spend 4–7 months of inactivity and anorexia without undergoing muscle atrophy and protein loss. A few known factors contribute to the sustaining of muscle tissue. During the summer, bears take advantage of the nutrition availability and accumulate muscle protein. The protein balance at time of dormancy is also maintained by lower levels of protein breakdown during the winter.
1993/2614) Northampton Community Healthcare National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2615) Bishop Auckland Hospitals National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2616) Carlisle Hospitals National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2617) Cheviot and Wansbeck National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2618) City Hospitals Sunderland National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2619) West Cheshire National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2620) South Kent Community Healthcare National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2621) Stockport Acute Services National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2622) Guild Community Healthcare National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2623) North Tyneside Health Care National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2624) Preston Acute Hospitals National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2625) Tameside and Glossop Community and Priority Services National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2626) Hartlepool and Peterlee Hospitals National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2627) Stockport Healthcare National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2628) New Possibilities National Health Service Trust (Establishment) Order 1993 (S.I.
=== From end-of-life batteries === A few small companies are recycling spent batteries, focusing on recovering copper and cobalt. Some recover lithium carbonate alongside the compound Li2Al4(CO3)(OH)12⋅3H2O also.
For example, γδ T cells express a T-cell receptor comprising γ and δ chains instead of the α and β chains that conventional T cell receptors use, and they are able to recognize antigen without the need for presenting it on MHC proteins (though some have shown the ability to recognize MHC-presented antigens), instead having a mode of recognition that resembles that of antibodies, or recognizing phosphoantigens (antigens that are phosphorylated) through butyrophilin. Mucosa-associated invariant T cells (MAIT) cells recognize ligands presented by the MHC-related protein MR1, which presents metabolites of riboflavin, pyridoxine, and folates. NKT cells recognize glycolipid antigens presented on CD1d, most prominently α-galactosylceramide. In contrast to T cell receptors, antibodies can recognize any type of molecule at virtually any size and can recognize either linear or conformational epitopes (the amino acids that comprise an epitope do not need to be next to each other in the primary structure but do need to be near one another when the protein is folded). At the molecular level, an antigen can be characterized by its ability to bind to an antibody's paratopes. Different antibodies have the potential to discriminate among specific epitopes present on the antigen surface.
At menopause, breast atrophy occurs. The breasts can decrease in size when the levels of circulating estrogen decline. The adipose tissue and milk glands also begin to wither. The breasts can also become enlarged from adverse side effects of combined oral contraceptive pills. The size of the breasts can also increase and decrease in response to weight fluctuations. Physical changes to the breasts are often recorded in the stretch marks of the skin envelope; they can serve as historical indicators of the increments and the decrements of the size and volume of a woman's breasts throughout the course of her life. Breast changes during menopause are sometimes treated with hormone replacement therapy.
Sources: en.wikipedia.org
In an early media report on MDMA published in 1982, a Drug Enforcement Administration (DEA) spokesman stated the agency would ban the drug if enough evidence for abuse could be found. By mid-1984, MDMA use was becoming more noticed. Bill Mandel reported on "Adam" in a 10 June San Francisco Chronicle article, but misidentified the drug as methyloxymethylenedioxyamphetamine (MMDA). In the next month, the World Health Organization identified MDMA as the only substance out of twenty phenethylamines to be seized a significant number of times. After a year of planning and data collection, MDMA was proposed for scheduling by the DEA on 27 July 1984, with a request for comments and objections. The DEA was surprised when a number of psychiatrists, psychotherapists, and researchers objected to the proposed scheduling and requested a hearing. In a Newsweek article published the next year, a DEA pharmacologist stated that the agency had been unaware of its use among psychiatrists. An initial hearing was held on 1 February 1985 at the DEA offices in Washington, D.C., with administrative law judge Francis L. Young presiding. It was decided there to hold three more hearings that year: Los Angeles on 10 June, Kansas City, Missouri on 10–11 July, and Washington, D.C., on 8–11 October. Sensational media attention was given to the proposed criminalization and the reaction of MDMA proponents, effectively advertising the drug.
Reverse vaccinology is an improvement of vaccinology that employs bioinformatics and reverse pharmacology practices, pioneered by Rino Rappuoli and first used against Serogroup B meningococcus. Since then, it has been used on several other bacterial vaccines.
Deman acknowledges that Wolverine is a gruff loner who often takes leave from the X-Men to deal with personal issues or problems, irreverent and rebellious towards authority figures, and displays a wry, sarcastic sense of humor. Despite this, Deman also notes that Wolverine is a reliable ally and competent leader, as well as capable of warmth, compassion, and empathy. Clinical psychologist and Navy veteran Larry Yarbrough recognizes that while "Logan has an extremely reactive temper" he is "also a kind person", pointing out that the "violent/kind demeanor" he displays is typical of combat veterans. According to him, Wolverine's "violent mood swings are a symptom of trauma, not a reflection of his character". He also observes Wolverine's habitual smoking and drinking, which are coping mechanisms for his traumatic experiences. Psychologist Suzana E. Flores writes that Wolverine demonstrates clinical psychological symptoms of post-traumatic stress disorder, bipolar disorder, antisocial personality disorder, dissociative disorder, and even sociopathy, but does so in a way that can be understood and empathized. She interprets his origin story as a depiction of complex childhood trauma, and its effects of dissociative amnesia and hypervigilance. She argues that his first formative trauma was his poor relationship with his mother, who was unable to properly attach to him because she lost her first son. In adulthood, he also suffered the trauma of torture by the Weapon X program.
On the other hand, the findings of animal studies of methenamine and carcinogenicity have also been questioned by some authors, though this topic is controversial. Antibiotics are known to disrupt the gut, urinary tract, and vaginal microbiota. This has been associated with increased risk of recurrent UTIs. Methenamine has been limitedly studied in this regard, but was found in one small study to preserve urinary microbial diversity. However, more studies are needed to assess the influence of methenamine on the host microbiome, both in the urinary tract and elsewhere in the body. Side effects of the topical form of methenamine for hyperhidrosis include dry skin, among others.
Sources: en.wikipedia.org
The sequence corresponds to a fragment of a protein found in human gastric juice, so related sequences are natural. The isolated fifteen-amino-acid peptide supplied for research is produced synthetically. Whether the free fragment circulates naturally in humans has not been settled.
In most jurisdictions it is not an approved medicine and is handled as a research material. Import and sale rules differ by country, and some regulators have placed it in categories that restrict human use. Status can change, so current local rules apply.
Rodent models dominate, particularly rats with induced gastric lesions, tendon injury, or vascular disruption. These designs allow controlled comparison but differ anatomically and metabolically from humans. Results from such models are commonly cited as preliminary.
It is a synthetic peptide built from fifteen amino acids, with a mass of roughly 1419 daltons. The sequence is reported to match a fragment of a protein present in human gastric juice. It is not a naturally circulating hormone.